Meeting
2020 ASCO Virtual Scientific Program
Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors.
Presenter
Mridula Krishnan, MBBS
University of Nebraska Medical Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
End-of-Life Care
Citation
J Clin Oncol 38: 2020 (suppl; abstr 12028)
DOI
10.1200/JCO.2020.38.15_suppl.12028
Abstract #
12028
Poster Bd #
316
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.
Speaker: Arthur Daban
Videos & Slides
2020 ASCO Virtual Scientific Program
A phase Ib/II, multicenter, open-label study of DSP-7888 dosing emulsion in combination with immune checkpoint inhibitors (CPI) nivolumab or pembrolizumab in adult patients (pts) with advanced solid tumors, including platinum-resistant ovarian cancer (PROC).
Speaker: Makoto Origuchi
Videos & Slides
2024 ASCO Annual Meeting
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).
Speaker: Anthony B. El-Khoueiry, MD
Videos & Slides
2024 ASCO Annual Meeting
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.
Speaker: Xiaoyu Li, MD